Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes.

Published

Journal Article

PURPOSE: To investigate, in the treatment of uveal melanomas, how tumor control, radiation toxicity, and visual outcomes are affected by the radiation dose at the tumor apex. METHODS AND MATERIALS: A retrospective review was performed to evaluate patients treated for uveal melanoma with (125)I plaques between 1988 and 2010. Radiation dose is reported as dose to tumor apex and dose to 5 mm. Primary endpoints included time to local failure, distant failure, and death. Secondary endpoints included eye preservation, visual acuity, and radiation-related complications. Univariate and multivariate analyses were performed to determine associations between radiation dose and the endpoint variables. RESULTS: One hundred ninety patients with sufficient data to evaluate the endpoints were included. The 5-year local control rate was 91%. The 5-year distant metastases rate was 10%. The 5-year overall survival rate was 84%. There were no differences in outcome (local control, distant metastases, overall survival) when dose was stratified by apex dose quartile (<69 Gy, 69-81 Gy, 81-89 Gy, >89 Gy). However, increasing apex dose and dose to 5-mm depth were correlated with greater visual acuity loss (P=.02, P=.0006), worse final visual acuity (P=.02, P<.0001), and radiation complications (P<.0001, P=.0009). In addition, enucleation rates were worse with increasing quartiles of dose to 5 mm (P=.0001). CONCLUSIONS: Doses at least as low as 69 Gy prescribed to the tumor apex achieve rates of local control, distant metastasis-free survival, and overall survival that are similar to radiation doses of 85 Gy to the tumor apex, but with improved visual outcomes.

Full Text

Duke Authors

Cited Authors

  • Perez, BA; Mettu, P; Vajzovic, L; Rivera, D; Alkaissi, A; Steffey, BA; Cai, J; Stinnett, S; Dutton, JJ; Buckley, EG; Halperin, E; Marks, LB; Mruthyunjaya, P; Kirsch, DG

Published Date

  • May 1, 2014

Published In

Volume / Issue

  • 89 / 1

Start / End Page

  • 127 - 136

PubMed ID

  • 24613808

Pubmed Central ID

  • 24613808

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2014.01.026

Language

  • eng

Conference Location

  • United States